Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Kivu Bioscience Inc.
AstraZeneca
ViroMissile, Inc.
EMD Serono
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
MacroGenics
Avacta Life Sciences Ltd
SystImmune Inc.
SN BioScience
Oscotec Inc.
Fusion Pharmaceuticals Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd.
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Eli Lilly and Company
Shanghai Bao Pharmaceuticals Co., Ltd.
Allist Pharmaceuticals, Inc.
Columbia University
Tata Memorial Hospital
Tvardi Therapeutics, Incorporated
Turnstone Biologics, Corp.
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
NantBioScience, Inc.
Prelude Therapeutics
Gene Surgery LLC
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Eisai Inc.
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Emory University
Fate Therapeutics
Mayo Clinic
Oncorus, Inc.